File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Managing complications of liver cirrhosis and portal hypertension
Title | Managing complications of liver cirrhosis and portal hypertension |
---|---|
Authors | |
Issue Date | 2016 |
Publisher | Malaysian Society of Gastroenterology & Hepatology. |
Citation | The 2016 Annual Scientific Congress of Malaysian Society of Gastroenterology and Hepatology (MSGH) - GUT 2016, Kuala Lumpur, Malaysia, 22-24 July 2016. In Souvenir Programme and Abstract Book, 2016, p. 39 How to Cite? |
Abstract | In patients with decompensated cirrhosis, the development of variceal bleeding or hepatorenal syndrome (HRS) is often associated with poor outcome and high mortality rates without liver transplantation. Variceal bleeding occurs at a rate of approximately 5-15% per year in those with established cirrhosis, and treatment comprises of general supportive measures, pharmacological therapy, endoscopic therapy, and rescue therapy for those who have failed pharmacologic and endoscopic therapies.
For those with cirrhosis and ascites, the annual in incidence of hepatorenal syndrome (HRS) is an estimated 8%, with a prevalence rate ranging from 13% to 45%. The prognosis is generally poor, with survival usually measured in weeks and months for type 1 and 2 HRS respectively. The pathophysiology of HRS is largely an effect of peripheral vasodilatation, and therefore the primary medical therapy employs the use of vasoconstrictor therapy to improve renal perfusion. The use of albumin increases the effective arterial blood volume, further augmenting the effect of vasoconstrictor therapy. For those
that relapse after stopping therapy, re-treatment is often effective, and may be required over a prolonged period as a bridge to liver transplantation.
The ultimate treatment for decompensated cirrhosis and HRS is liver transplantation, which significantly improves long-term survival. Therefore, timely referral to a transplant center is essential. |
Description | Lecture 4 |
Persistent Identifier | http://hdl.handle.net/10722/235753 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, JYY | - |
dc.date.accessioned | 2016-10-17T02:53:00Z | - |
dc.date.available | 2016-10-17T02:53:00Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | The 2016 Annual Scientific Congress of Malaysian Society of Gastroenterology and Hepatology (MSGH) - GUT 2016, Kuala Lumpur, Malaysia, 22-24 July 2016. In Souvenir Programme and Abstract Book, 2016, p. 39 | - |
dc.identifier.uri | http://hdl.handle.net/10722/235753 | - |
dc.description | Lecture 4 | - |
dc.description.abstract | In patients with decompensated cirrhosis, the development of variceal bleeding or hepatorenal syndrome (HRS) is often associated with poor outcome and high mortality rates without liver transplantation. Variceal bleeding occurs at a rate of approximately 5-15% per year in those with established cirrhosis, and treatment comprises of general supportive measures, pharmacological therapy, endoscopic therapy, and rescue therapy for those who have failed pharmacologic and endoscopic therapies. For those with cirrhosis and ascites, the annual in incidence of hepatorenal syndrome (HRS) is an estimated 8%, with a prevalence rate ranging from 13% to 45%. The prognosis is generally poor, with survival usually measured in weeks and months for type 1 and 2 HRS respectively. The pathophysiology of HRS is largely an effect of peripheral vasodilatation, and therefore the primary medical therapy employs the use of vasoconstrictor therapy to improve renal perfusion. The use of albumin increases the effective arterial blood volume, further augmenting the effect of vasoconstrictor therapy. For those that relapse after stopping therapy, re-treatment is often effective, and may be required over a prolonged period as a bridge to liver transplantation. The ultimate treatment for decompensated cirrhosis and HRS is liver transplantation, which significantly improves long-term survival. Therefore, timely referral to a transplant center is essential. | - |
dc.language | eng | - |
dc.publisher | Malaysian Society of Gastroenterology & Hepatology. | - |
dc.relation.ispartof | Annual Scientific Congress of Malaysian Society of Gastroenterology & Hepatology, GUT 2016 | - |
dc.title | Managing complications of liver cirrhosis and portal hypertension | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.hkuros | 260424 | - |
dc.identifier.spage | 39 | - |
dc.identifier.epage | 39 | - |
dc.publisher.place | Malaysia | - |